{ "docId": "019de075-814d-76ed-b6e6-6e437a6b6631", "docSlug": "56480dbdf83cce5ae4f2fad948f0ee58", "documentTitle": "Dare Bioscience | Investor Presentation Deck | 26 slides", "authorId": "dare-bioscience", "authorName": "Daré Bioscience", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "pageCount": 26, "prevPage": 7, "nextPage": 9, "slideType": "problem_statement", "function": "frame_problem", "density": "dense", "nDataPoints": 4, "notes": "The slide uses a comparison to erectile dysfunction to frame the market opportunity.", "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de075-814d-76ed-b6e6-6e437a6b6631/8", "deckHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631", "deckJsonHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631.json", "deckAnchorHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631#slide-8", "components": [ { "bbox": { "h": 0.08, "w": 0.6, "x": 0.2, "y": 0.75 }, "kind": "callout", "text": "There are no FDA-approved treatments for FSAD/FSIAD", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d379234b-f607-41f9-898f-c32a8edab7b5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.85 }, "kind": "disclaimer", "text": "1. Diagnostic and Statistical Manual (DSM) 4th Edition Text Revision (DSM IV TR) defines FSAD as a persistent or recurrent inability to attain or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement. The diagnostic criteria also state that the inability causes marked distress or interpersonal difficulty, is not better accounted for by another Axis I disorder (except another sexual dysfunction) and is not due exclusively to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition. As described in the fifth edition of the DSM (DSM 5), which was published in 2013, FSIAD is characterized as lack of, or significantly reduced, sexual interest and/or arousal for at least six months and the symptoms must be severe enough to cause clinically significant distress. Patients could meet the DSM 5 criteria for FSIAD if they predominantly have symptoms of low sexual interest, if they predominantly have symptoms of low sexual arousal, or if they predominantly have symptoms of both low sexual desire and low sexual arousal. 2. https://labs.la.utexas.edu/mestonlab/female-sexual-interestarousal-disorders/, accessed 8 August 2023 3. https://my.clevelandclinic.org/health/diseases/24640-anorgasmia, accessed 8 August 2023 4. McCool et al. Sex Med Rev 2016;4:197-212. DOI: 10.1016/j.sxmr.2016.03.002 5. Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. 6. Based on US Census projections for 2016.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f83b4a63-fb19-4f89-9182-44a737483068", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.52, "y": 0.18 }, "kind": "list", "text": "Meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%. Market research estimates: 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal. 10 million women are considered distressed and actively seeking treatment.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2eb62b64-d25a-4979-a90f-b2e56fe140ce", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.05, "y": 0.18 }, "kind": "list", "text": "Female Sexual Arousal Disorder (FSAD) is characterized primarily by inability to attain or maintain sufficient genital arousal during sexual activity and, Female Sexual Interest/Arousal Disorder (FSIAD) is defined in the DSM-5 as lack of, or significantly reduced, sexual interest/arousal. Of female sexual function disorders, these conditions are those most analogous to erectile dysfunction (ED) in men. Arousal disorders in women should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctions, such as orgasmic disorder (anorgasmia) and hypoactive sexual desire disorder (HSDD), which is characterized in DSM-IV-TR as lack or absence of sexual fantasies and desire for sexual activity for some period of time.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "aa24f1ed-a7ab-4d72-9dc7-d25f1b567032", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.64, "x": 0.18, "y": 0.03 }, "kind": "title", "text": "FSAD/FSIAD – The Clinical Issue & Prevalence", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e1ca5fad-9990-4bbc-93b1-13776516fced", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "agent": "Architect", "layer": "slide", "matchId": "63ce8606-bbcb-4aef-8e39-ce555aadd0c0", "evidence": "Female Sexual Arousal Disorder (FSAD) is characterized primarily by inability to attain or maintain sufficient genital arousal during sexual activity", "confidence": 0.7 } ], "frameworks": [ { "name": "argument-from-analogy", "slug": null, "matchId": "ef04e9f6-209c-4a71-bc43-746e83186b8a", "evidence": "Comparison of FSAD/FSIAD to erectile dysfunction (ED) in men.", "confidence": 0.9 } ], "arcBeats": [ { "to": 8, "from": 8, "beatId": "7d9cc53d-18a2-4032-9a7e-ce50d00a7876", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The deck presents a clear problem statement on page 8", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 9, "from": 7, "beatId": "188fa255-ca44-4d79-b6ab-0aff1c2bb57b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents solutions, including Sildenafil Cream, 3.6%, on pages 7-9", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "loops": [ { "to": 11, "from": 8, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "83faa245-7d21-49f3-aa4d-68f21da0e116", "evidence": "The deck presents the consequences of not addressing FSAD/FSIAD on pages 8-11", "position": 0, "objective": "Highlight the need for a treatment for FSAD/FSIAD", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }